Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Treatment Patterns Across Lines of Therapy for Advanced Non-Small Cell Lung Cancer in the United States.

Cancer medicine - 1 Apr 2026

Lee Do H, Li Yimeng, Yang Szu-Chun, Chiang Anne C, Soulos Pamela R, Gross Cary P, Wang Shi-Yi

Abstract excerpt

INTRODUCTION: Treatment strategies for advanced non-small cell lung cancer (aNSCLC) have evolved, but little is known about real-world approaches by biomarker groups across different lines of therapy (LOTs), particularly regarding discontinuation rates as a measure of effectiveness and tolerability. METHODS: Using deidentified patient data from the Flatiron Health electronic health record-derived database, we...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anaplastic Lymphoma Kinase
Share to B7-H1 Antigen

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Biomarkers, Tumor

Share to Carcinoma, Non-Small-Cell Lung

Share to ErbB Receptors

Share to Gene Rearrangement

Share to Lung Neoplasms

Share to United States

Source

Open in PubMed Open full text

Identifiers

PMID: 42007970
DOI: 10.1002/cam4.71736
PMCID: PMC13094514

Genes

ALK
EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Treatment Patterns Across Lines of Therapy for Advanced Non-Small Cell Lung Cancer in the United States.PMID 42007970Read ↗

Real-world treatment patterns and attrition for non-driver mutation metastatic non-small cell lung cancer in the US.Semantic proximity Read ↗

Retrospective Analysis of Real-World Treatment Patterns and Clinical Outcomes in Patients With Advanced Non-Small Cell Lung Cancer Starting First-Line Systemic Therapy in the United KingdomSemantic proximity Read ↗

Metastatic non-small-cell lung cancer without driver mutations: projections by therapy line in Western Europe, 2021-2026.Semantic proximity Read ↗

First-line treatment patterns and real-world outcomes in patients with advanced KRAS-mutated non-small cell lung cancer with high unmet need.Semantic proximity Read ↗

Real-World Prevalence, Treatment Patterns, and Outcomes for Patients With HER2 (ERBB2)-Mutant Metastatic Non-Small Cell Lung Cancer, From a US-Based Clinico-Genomic Database.Semantic proximity Read ↗

Patient Characteristics, Testing and Treatment Patterns, and Outcomes in EGFR-Mutated Advanced Non-Small Cell Lung Cancer: A Multinational, Real-World Study.Semantic proximity Read ↗

Real-World Outcomes and Clinical Heterogeneity of First-Line Immunochemotherapy in Extensive-Stage Small-Cell Lung CancerSemantic proximity Read ↗

Timeliness of EGFR/ALK Inhibitor Treatment and Survival in Lung Cancer: A Population-Based Analysis.Semantic proximity Read ↗

Prospective cohort study of clinical characteristics and management patterns for patients with non-small-cell lung cancer in the Russian Federation: EPICLIN-Lung.Semantic proximity Read ↗

Assessing Second-Line Treatment Strategies and Outcomes in Epidermal Growth Factor Receptor (EGFR) Oncogene-Driven Stage IV Non-Small Cell Lung Cancer, Following a First-Line EGFR-TKI Therapy.Semantic proximity Read ↗

Discontinuation of Immune Checkpoint Inhibitor and Survival in Patients With Non-small-cell Lung Cancer Without a Driver Gene Mutation.Semantic proximity Read ↗

[Annual therapeutic advances in advanced non-small cell lung cancer in 2024].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.